These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 9014719)

  • 1. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate cancer development after transurethral resection of the prostate--histopathological studies of radical prostatectomy specimens].
    Kanno H; Umemoto S; Izumi K; Hasumi H; Osada Y; Ohta J; Mikata K; Tuchiya F
    Nihon Hinyokika Gakkai Zasshi; 2006 May; 97(4):649-59. PubMed ID: 16768146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does screening for prostate cancer identify clinically important disease?
    Feneley MR
    Ann R Coll Surg Engl; 1999 May; 81(3):207-14. PubMed ID: 10364958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early diagnosis of prostate cancer in the Western Cape.
    Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
    S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
    Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
    Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
    Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
    Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
    Ohori M; Goad JR; Wheeler TM; Eastham JA; Thompson TC; Scardino PT
    J Urol; 1994 Nov; 152(5 Pt 2):1843-9. PubMed ID: 7523732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
    Rogers E; Ohori M; Kassabian VS; Wheeler TM; Scardino PT
    J Urol; 1995 Jan; 153(1):104-10. PubMed ID: 7526002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
    Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
    Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
    Epstein JI; Walsh PC; Carmichael M; Brendler CB
    JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
    Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK
    Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.